{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:19:17Z","timestamp":1793366357446,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.humpath.2009.09.017","type":"journal-article","created":{"date-parts":[[2010,2,15]],"date-time":"2010-02-15T06:38:52Z","timestamp":1266215932000},"page":"794-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma"],"prefix":"10.1016","volume":"41","author":[{"given":"Mari","family":"Bunkholt Elstrand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiep Phuc","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"\u00d8degaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arild","family":"Holth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Elloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes G.","family":"Trop\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.humpath.2009.09.017_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ijgc-00009577-200505001-00002","article-title":"Treatment goals in ovarian cancer","volume":"15","author":"Ozols","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2009.09.017_bib2","series-title":"Cancer incidence mortality survival and prevalence","first-page":"2007","author":"Cancer in Norway","year":"2006"},{"key":"10.1016\/j.humpath.2009.09.017_bib3","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2009.09.017_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0065-230X(05)94004-9","article-title":"Apoptotic pathways and therapy resistance in human malignancies","volume":"94","author":"Viktorsson","year":"2005","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.humpath.2009.09.017_bib5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1615\/CritRevOncog.v13.i3.10","article-title":"Biological characteristics of cancers involving the serosal cavities","volume":"13","author":"Davidson","year":"2007","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.humpath.2009.09.017_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/gyno.1995.1027","article-title":"The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer","volume":"56","author":"Makar","year":"1995","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2009.09.017_bib7","first-page":"409","article-title":"The microenvironment of the tumour-host interface","volume":"271","author":"Liotta","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2009.09.017_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase-Akt pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2009.09.017_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2009.09.017_bib10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2005.11.042","article-title":"PTEN function in normal and neoplastic growth","volume":"241","author":"Chow","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.humpath.2009.09.017_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","article-title":"Activation of AKT kinases in cancer: implications for therapeutic targeting","volume":"94","author":"Bellacosa","year":"2005","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.humpath.2009.09.017_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","article-title":"The activation of Akt\/PKB signaling pathway and cell survival","volume":"9","author":"Song","year":"2005","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.humpath.2009.09.017_bib13","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2004.01.103","article-title":"Putting the rap on Akt","volume":"22","author":"Thompson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2009.09.017_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2009.09.017_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.coph.2008.08.004","article-title":"Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.humpath.2009.09.017_bib16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.humpath.2009.09.017_bib17","first-page":"196","article-title":"Overexpression of AKT2\/protein kinase B\u03b2 leads to up-regulation of \u03b21 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells","volume":"63","author":"Arboleda","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2009.09.017_bib18","first-page":"407","article-title":"Overexpression of Akt\/AKT can modulate chemotherapy-induced apoptosis","volume":"20","author":"Page","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.humpath.2009.09.017_bib19","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"23","author":"Altomare","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2009.09.017_bib20","first-page":"1087","article-title":"Inhibition of phosphatidylinositol 3\u2032-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models","volume":"62","author":"Hu","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2009.09.017_bib21","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2009.09.017_bib22","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1158\/1535-7163.MCT-07-0237","article-title":"Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer","volume":"6","author":"Huynh","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2009.09.017_bib23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ijc.2910640412","article-title":"Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas","volume":"64","author":"Bellacosa","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2009.09.017_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-4608(95)00248-0","article-title":"Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies","volume":"87","author":"Thompson","year":"1996","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.humpath.2009.09.017_bib25","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0002-9440(10)64681-0","article-title":"Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas","volume":"158","author":"Kurose","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2009.09.017_bib26","first-page":"1409","article-title":"Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis","volume":"20","author":"Noske","year":"2008","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2009.09.017_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9440(10)61714-2","article-title":"AKT1\/PKB kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells","volume":"159","author":"Sun","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2009.09.017_bib28","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/cncr.22195","article-title":"Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer","volume":"107","author":"Castellvi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2009.09.017_bib29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1349-7006.2007.00492.x","article-title":"Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP\/MVP and P-glycoprotein expression","volume":"98","author":"Oda","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2009.09.017_bib30","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1440-1827.2008.02306.x","article-title":"Increased staining for phosphorylated AKT and nuclear factor\u2013kappaB p65 and their relationship with prognosis in epithelial ovarian cancer","volume":"58","author":"Guo","year":"2008","journal-title":"Pathol Int"},{"key":"10.1016\/j.humpath.2009.09.017_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00428-006-0358-3","article-title":"Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer","volume":"450","author":"Woenckhaus","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2009.09.017_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1309\/BL7EMW66LQX6GFRP","article-title":"Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas","volume":"124","author":"Wang","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2009.09.017_bib33","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/00000478-200111000-00008","article-title":"The role of Desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells","volume":"25","author":"Davidson","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2009.09.017_bib34","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nprot.2008.77","article-title":"Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry","volume":"3","author":"Dong","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.humpath.2009.09.017_bib35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cyto.b.20172","article-title":"Flow cytometric immunophenotyping of epithelial cancer cells in effusions- technical considerations and pitfalls","volume":"72B","author":"Dong","year":"2007","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.humpath.2009.09.017_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumor EORTC; National Cancer Institute of United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2009.09.017_bib37","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer): Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2009.09.017_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ccr.2005.02.010","article-title":"DJ-1, a novel regulator of the tumor suppressor PTEN","volume":"7","author":"Kim","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2009.09.017_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.humpath.2007.05.014","article-title":"Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma","volume":"39","author":"Davidson","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2009.09.017_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1073\/pnas.0812745106","article-title":"DJ-1\/PARK7 is an important mediator of hypoxia-induced cellular responses","volume":"106","author":"Vasseur","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2009.09.017_bib41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.22426","article-title":"Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma","volume":"109","author":"Kleinberg","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2009.09.017_bib42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/1078-0432.CCR-05-2516","article-title":"Proteomic profiling of malignant ovarian cancer effusions: survival and injury pathways discriminate clinical outcome","volume":"12","author":"Davidson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2009.09.017_bib43","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.20946","article-title":"Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma","volume":"103","author":"Elloul","year":"2005","journal-title":"Cancer"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817709004262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817709004262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:32:16Z","timestamp":1758645136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817709004262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0046817709004262"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2009.09.017","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2009.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}